Copy number aberrations in benign serous ovarian tumors: A case for reclassification?

Clinical Cancer Research

Volumn 17, Issue 23, 2011, Pages 7273-7282

  Hunter, Sally M ^a   Anglesio, Michael S ^e   Sharma, Raghwa ^c   Gilks, C Blake ^e   Melnyk, Nataliya ^e   Chiew, Yoke Eng ^c,d   DeFazio, Anna ^c,d   Longacre, Teri A ^f   Huntsman, David G ^e   Gorringe, Kylie L ^a,b   Campbell, Ian G ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BENIGN SEROUS OVARY TUMOR; BENIGN TUMOR; CARCINOGENESIS; CHROMOSOME 12; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; COHORT ANALYSIS; CONTROLLED STUDY; COPY NUMBER ABERRATION; CYSTADENOFIBROMA; CYSTADENOMA; DNA SEQUENCE; EPITHELIOID CELL; FEMALE; FIBROBLAST; GENOMICS; HIGH RESOLUTION COPY NUMBER ANALYSIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY TUMOR; PRIORITY JOURNAL; TUMOR CLASSIFICATION;

ADENOFIBROMA; BASE SEQUENCE; CYSTADENOMA, SEROUS; DNA COPY NUMBER VARIATIONS; EPITHELIUM; FEMALE; HUMANS; OVARIAN NEOPLASMS; OVARY; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA; SEROUS MEMBRANE;

EID: 82555189392     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2080     Document Type: Article

References (52)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Averette HE, Janicek MF, Menck HR. The National Cancer Data Base report on ovarian cancer. American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1995;76:1096-103.
3. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30. (Pubitemid 40310185)
4. Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, Sakamaki S, et al. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 1998;339:1277-84. (Pubitemid 28496193)
5. Blaustein A, Kaganowicz A, Wells J. Tumor markers in inclusion cysts of the ovary. Cancer 1982;49:722-6. (Pubitemid 12165429)
6. Singer G, Kurman RJ, Chang HW, Cho SK, Shih Ie M. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002;160:1223-8. (Pubitemid 34411626)
7. Pothuri B, Leitao MM, Levine DA, Viale A, Olshen AB, Arroyo C, et al. Genetic analysis of the early natural history of epithelial ovarian carcinoma. PLoS One 2010;5:e10358.
8. Korner M, Burckhardt E, Mazzucchelli L. Different proportions of aneusomic cells in ovarian inclusion cysts associated with serous borderline tumours and serous high-grade carcinomas support different pathogenetic pathways. J Pathol 2005;207:20-6. (Pubitemid 41200710)
9. Barakat RR, Markman M, Randall ME, editors. Principles and practice of gynecologic oncology. Philadelphia: Lippincott Williams & Wilkins; 2009.
10. Kurman RJ, Hedrick Ellenson L,Ronnett BM, editors. Blaustein's pathology of the female genital tract. New York: Springer; 2011. p. 1173.
11. Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008;5:e232.
12. Gilks CB, Ionescu DN, Kalloger SE, Kobel M, Irving J, Clarke B, et al. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol 2008;39:1239-51.
13. Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004;164:1511-8. (Pubitemid 38529752)
14. Ho CL, Kurman RJ, Dehari R, Wang TL, Shih Ie M. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res 2004;64:6915-8. (Pubitemid 39330999)
15. Teneriello MG, Ebina M, Linnoila RI, Henry M, Nash JD, Park RC, et al. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res 1993;53:3103-8. (Pubitemid 23210320)
16. Singer G, Oldt R III, Cohen Y, Wang BG, Sidransky D, Kurman RJ, et al. Mutations in BRAF and KRAS characterize the development of lowgrade ovarian serous carcinoma. J Natl Cancer Inst 2003;95:484-6. (Pubitemid 36432423)
17. Sieben NL, Macropoulos P, Roemen GM, Kolkman-Uljee SM, Jan Fleuren G, Houmadi R, et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumors. J Pathol 2004;202:336-40. (Pubitemid 38325243)
18. Kuo KT, Guan B, Feng Y, Mao TL, Chen X, Jinawath N, et al. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res 2009;69:4036-42.
19. Singer G, Stohr R, Cope L, Dehari R, Hartmann A, Cao DF, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 2005;29:218-24. (Pubitemid 40170640)
20. Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, et al. The distal fallopian tube: anew model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 2007;19:3-9. (Pubitemid 46095865)
21. Tone AA, Begley H, Sharma M, Murphy J, Rosen B, Brown TJ, et al. Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma. Clin Cancer Res 2008;14:4067-78.
22. Carlson J, Roh MH, Chang MC, Crum CP. Recent advances in the understanding of the pathogenesis of serous carcinoma: the concept of low- and high-grade disease and the role of the fallopian tube. Diagn Histopathol (Oxf) 2008;14:352-65.
23. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 2007;31:161-9. (Pubitemid 46175016)
24. Bryan EJ, Watson RH, Davis M, Hitchcock A, Foulkes WD, Campbell IG. Localization of an ovarian cancer tumor suppressor gene to a 0.5-cM region between D22S284 and CYP2D, on chromosome 22q. Cancer Res 1996;56:719-21. (Pubitemid 26055458)
25. Merritt MA, Green AC, Nagle CM, Webb PM. Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 2008;122:170-6.
26. Wang Y, Carlton VE, Karlin-Neumann G, Sapolsky R, Zhang L, Moorhead M, et al. High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays. BMC Med Genomics 2009;2:8.
27. Hardenbol P, Yu F, Belmont J, Mackenzie J, Bruckner C, Brundage T, et al. Highly multiplexed molecular inversion probe genotyping: over 10,000 targeted SNPs genotyped in a single tube assay. Genome Res 2005;15:269-75. (Pubitemid 40309391)
28. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010;363:1532-43.
29. Qiu W, Hu M, Sridhar A, Opeskin K, Fox S, Shipitsin M, et al. No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet 2008;40:650-5. (Pubitemid 351601206)
30. Roy WJ Jr, Watson RH, Hitchcock A, Campbell IG. Frequent loss of heterozygosity on chromosomes 7 and 9 in benign epithelial ovarian tumors. Oncogene 1997;15:2031-5. (Pubitemid 27489130)
31. Thomas NA, Neville PJ, Baxter SW, Campbell IG. Genetic analysis of benign ovarian tumors. Int J Cancer 2003;105:499-505. (Pubitemid 36578554)
32. Antill YC, Mitchell G, Johnson SA, Devereux L, Milner A, Phillips KA, et al. Loss of heterozygosity analysis in ductal lavage samples from BRCA1 and BRCA2 carriers: a cautionary tale. Cancer Epidemiol Biomarkers Prev 2006;15:1396-8. (Pubitemid 44125299)
33. Cheng EJ, Kurman RJ, Wang M, Oldt R, Wang BG, Berman DM, et al. Molecular genetic analysis of ovarian serous cystadenomas. Lab Invest 2004;84:778-84. (Pubitemid 38715477)
34. Pradhan M, Davidson B, Trope CG, Danielsen HE, Abeler VM, Risberg B. Gross genomic alterations differ between serous borderline tumors and serous adenocarcinomas-an image cytometric DNA ploidy analysis of 307 cases with histogenetic implications. Virchows Arch 2009;454:677-83.
35. Mayr D, Hirschmann A, Lohrs U, Diebold J. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol 2006;103:883-7. (Pubitemid 44821309)
36. Seidman JD, Mehrotra A. Benign ovarian serous tumors: a re-evaluation and proposed reclassification of serous "cystadenomas" and "cystadenofibromas". Gynecol Oncol 2005;96:395-401. (Pubitemid 40127140)
37. Fletcher JA, Gibas Z, Donovan K, Perez-Atayde A, Genest D, Morton CC, et al. Ovarian granulosa-stromal cell tumors are characterized by trisomy 12. Am J Pathol 1991;138:515-20.
38. Leung WY, Schwartz PE, Ng HT, Yang-Feng TL. Trisomy 12 in benign fibroma and granulosa cell tumor of the ovary. Gynecol Oncol 1990;38:28-31. (Pubitemid 20206221)
39. Mrozek K, Nedoszytko B, Babinska M, Mrozek E, Hrabowska M, Emerich J, et al. Trisomy of chromosome 12 in a case of thecoma of the ovary. Gynecol Oncol 1990;36:413-6. (Pubitemid 20116921)
40. Pejovic T, Heim S, Mandahl N, Elmfors B, Floderus UM, Furgyik S, et al. Trisomy 12 is a consistent chromosomal aberration in benign ovarian tumors. Genes Chromosomes Cancer 1990;2:48-52. (Pubitemid 20300435)
41. Persons DL, Hartmann LC, Herath JF, Keeney GL, Jenkins RB. Fluorescence in situ hybridization analysis of trisomy 12 in ovarian tumors. Am J Clin Pathol 1994;102:775-9.
42. Yang-Feng TL, Li SB, Leung WY, Carcangiu ML, Schwartz PE. Trisomy 12 and K-ras-2 amplification in human ovarian tumors. Int J Cancer 1991;48:678-81.
43. Liang JC, Kurzrock R, Gutterman JU, Gallick GE. Trisomy 12 correlates with elevated expression of p21 ras in a human adenosquamous carcinoma of the lung. Cancer Genet Cytogenet 1986;23:183-8.
44. Pickhardt PJ, Hanson ME. Incidental adnexal masses detected at lowdose unenhanced CT in asymptomatic women age 50 and older: implications for clinical management and ovarian cancer screening. Radiology 2010;257:144-50.
45. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004;432:332-7. (Pubitemid 39551661)
46. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004;303:848-51. (Pubitemid 38174665)
47. Ohuchida K, Mizumoto K, Murakami M, Qian LW, Sato N, Nagai E, et al. Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res 2004;64:3215-22. (Pubitemid 38581425)
48. Barcellos-Hoff MH, Ravani SA. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res 2000;60:1254-60. (Pubitemid 30151992)
49. Kuperwasser C, Chavarria T, Wu M, Magrane G, Gray JW, Carey L, et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci U S A 2004;101:4966-71. (Pubitemid 38469186)
50. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004;303:848-51. (Pubitemid 38174665)
51. Helou K, Padilla-Nash H, Wangsa D, Karlsson E, Osterberg L, Karlsson P, et al. Comparative genome hybridization reveals specific genomic imbalances during the genesis from benign through borderline to malignant ovarian tumors. Cancer Genet Cytogenet 2006;170:1-8. (Pubitemid 44332557)
52. Micci F, Haugom L, Ahlquist T, Andersen HK, Abeler VM, Davidson B, et al. Genomic aberrations in borderline ovarian tumors. J Transl Med 2010;8:21.